Apple plans to launch AI-powered search tool next year - Bloomberg
REHOVOT, Israel and HOBOKEN, N.J. -On Wednesday, Kamada Ltd . (NASDAQ:KMDA) the biopharmaceutical company reported fourth quarter earnings that beat analyst expectations, despite revenue coming in slightly below estimates.
The company’s shares gained 2.12% in premarket trading after the release.
The company, which specializes in plasma-derived therapies, posted adjusted earnings per share of $0.07 for Q4, topping the consensus forecast of $0.05. Revenue for the quarter was $39.0 million, just shy of the $40.11 million analysts were expecting.
For the full year 2024, Kamada reported record revenue of $161.0 million, up 13% from 2023. Adjusted EBITDA rose 42% to $34.1 million.
"Our performance over the course of 2024 was excellent, leading to record annual top- and bottom-line financial results," said CEO Amir London.
Looking ahead, Kamada reiterated its fiscal 2025 guidance, projecting revenue of $178-182 million. This outlook represents 12% year-over-year growth at the midpoint compared to 2024 results.
The company said it aims to leverage its strong financial position to pursue new business development and M&A opportunities in 2025. Kamada ended 2024 with $78.4 million in cash and cash equivalents.
Additionally, Kamada declared a special cash dividend of $0.20 per share, totaling approximately $11.5 million, payable on April 7, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.